Drug Approval | April 12, 2025
FDA approves Opdivo plus Yervoy as treatment metastatic colorectal cancer
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
Strengthening capabilities in Peptide Therapeutics and CDMO services
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
Subscribe To Our Newsletter & Stay Updated
